26/08/2026
Hadassah’s Sharett Institute of Oncology continues to bring innovation to some of the most complex areas of cancer care.
Dr. Philip Blumenfeld, Head of Advanced Radiation Therapy at Hadassah’s Sharett Oncology Institute, was invited to present at PTCOG64, the world’s leading conference on proton and particle therapy.
His presentation focused on a unique study of lung cancer patients requiring re-irradiation after previous radiation treatment, a highly complex group with limited treatment options and increased risk of toxicity.
The data showed how proton therapy, delivered through a specialised system that allows patients to be treated in a seated position, may offer greater precision, safety, and feasibility while helping protect healthy lung tissue.
Conducted in collaboration with P-Cure Ltd at the proton therapy centre in Shilat, this study reflects Hadassah’s commitment to combining advanced technology, clinical excellence, and personalised medicine for patients facing the most challenging cases.